B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

about

Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies

P2860

Q52687811-B409744D-9F62-4714-A9D2-E73140B5F556 Q58742654-D1CBDC58-F3C6-4E3C-BF03-56ED42F2E113

P2860

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

Item

http://www.wikidata.org/entity/Q50056654

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@en

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@nl

type

Item

label

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@en

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@nl

prefLabel

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@en

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@nl

P1476

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

@en

P2093

Dayson Moreira

http://www.w3.org/2001/XMLSchema#string

Haejung Won

http://www.w3.org/2001/XMLSchema#string

Hongwei H Yin

http://www.w3.org/2001/XMLSchema#string

Larry Kwak

http://www.w3.org/2001/XMLSchema#string

Marcin Kortylewski

http://www.w3.org/2001/XMLSchema#string

Piotr Swiderski

http://www.w3.org/2001/XMLSchema#string

Raju K Pillai

http://www.w3.org/2001/XMLSchema#string

Stephen Forman

http://www.w3.org/2001/XMLSchema#string

Tomasz Adamus

http://www.w3.org/2001/XMLSchema#string

Xingli Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleic acid-based approaches to STAT inhibition

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR)

Oncogenically active MYD88 mutations in human lymphoma

Coordinated regulation of myeloid cells by tumours

Toll-like receptor control of the adaptive immune responses

Cancer statistics, 2016

The National Cancer Data Base report on non-Hodgkin's lymphoma.

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.

P31

scholarly article

P356

10.1016/J.YMTHE.2018.01.007

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29433938

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Toll-like receptor

P932

5910676

http://www.w3.org/2001/XMLSchema#string

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

about

P2860

P2860

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932